1. FDA-CRCG hosted Free Virtual Public Workshop: Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches. September 30 – October 1, 2021. http://www.complexgenerics.org/PBPK2021. Accessed 8 May 2022.
2. Gong Y, Zhang P, Yoon M, Zhu H, Kohojkar A, Hooker AC, et al. Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: summary of workshop. CPT Pharmacometrics Syst Pharmacol. 2023;12(5):624–30.
3. Development of PBPK Model For Predicting Food Impact on Bioequivalence Assessment. Abdullah Al Shoyaib, Ph.D. Workshop: regulatory utility of mechanistic modeling to support alternative bioequivalence approaches, day 2 session 2: oral PBPK for evaluating the impact of food on bioequivalence. [Available from: https://www.complexgenerics.org/media/SOP/complexgenerics/pdf/Conference-Slides/D2-07%20Abdullah%20Al%20Shoyaib%20(PBPK%20Workshop-Food%20effect-D2-S2).pdf. Accessed 11 Dec 2023.
4. Walenga RL, Butler C, Craven BA, Longest PW, Mohamed R, Newman B, et al. Mechanistic modeling of generic orally inhaled drug products: a workshop summary report. CPT Pharmacometrics Syst Pharmacol. 2023;12(5):560–74.
5. FDA. Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives for Fiscal Year (FY) 2022 [Available from: https://www.fda.gov/media/154487/download. Accessed 11 Dec 2023.